10 November 2022 
EMA/CHMP/869021/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Eylea 
aflibercept 
On 10 November 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Eylea. The marketing authorisation holder for this medicinal product is Bayer AG. 
The CHMP adopted a new indication for the treatment of preterm infants with retinopathy of prematurity 
(ROP).  
For information, the full indications for Eylea will therefore be as follows:2 
Eylea is indicated for adults for the treatment of 
• 
• 
• 
• 
neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), 
visual impairment due to macular oedema secondary to retinal vein occlusion (branch 
RVO or central RVO) (see section 5.1), 
visual impairment due to diabetic macular oedema (DME) (see section 5.1), 
visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 
5.1). 
EYLEA is indicated in preterm infants for the treatment of 
• 
retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II 
(stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
